IFRX · InflaRx N.V.

InflaRx N.V., a Dutch public limited liability company, has executed a definitive underwriting agreement with Guggenheim Securities, LLC acting as representative for several underwriters to sell 75 million ordinary shares at a fixed purchase price of $1.88 each. This public offering is conducted under an effective Form F-3 shelf registration statement (File No. 333-273058), with a preliminary prospectus supplement dated May 6, 2026. The transaction structure ensures several liability among underwriters, with payment delivered via wire transfer to an authorized account of InflaRx Pharmaceuticals, Inc., and share delivery through DTC facilities. The closing is scheduled for May 7, 2026, at 10:00 A.M. New York time, or shortly thereafter by mutual agreement. A Dutch legal opinion from NautaDutilh N.V., dated May 7, 2026, affirms the company's valid existence and that the offered shares, upon full payment, will be validly issued, fully paid, and non-assessable under Dutch law, subject to standard qualifications on corporate authority and insolvency risks. This capital raise significantly dilutes existing shareholders but provides substantial gross proceeds of approximately $141 million before expenses, potentially bolstering the company's cash position for ongoing operations in its biopharmaceutical focus.